Salud financiera de hoja de balance de Jasper Therapeutics

Salud financiera controles de criterios 6/6

Jasper Therapeutics tiene un patrimonio de los accionistas total de $100.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $113.9M y $13.6M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$106.82m
Patrimonio	US$100.31m
Total pasivo	US$13.62m
Activos totales	US$113.93m

Actualizaciones recientes sobre salud financiera

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Feb 02

Recent updates

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Nov 28

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Nov 23

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($108.7M) de JSPR superan a sus pasivos a corto plazo ($10.1M).

Pasivo a largo plazo: Los activos a corto plazo de JSPR ($108.7M) superan a sus pasivos a largo plazo ($3.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: JSPR está libre de deudas.

Reducción de la deuda: JSPR no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: JSPR tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: JSPR dispone de suficiente cash runway para 1.2 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 33.1% cada año.

Salud financiera de hoja de balance de Jasper Therapeutics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jasper Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of Common Stock for Continued Listing on the Nasdaq Capital Market

Jasper Therapeutics Receives Written Notice from Nasdaq Regarding Minimum $1.00 Per Share Requirement

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Recent updates

New minor risk - Share price stability

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target increased by 7.7% to US$69.13

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

Asper Therapeutics, Inc Announces the Expansion of its Mast Cell Development Portfolio with Phase 1b/2a Study Evaluating Briquilimab in Asthma Patients

Jasper Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia

Jasper Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50.505 million.

New major risk - Share price stability

Jasper Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.505 million.

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Price target decreased by 11% to US$61.25

Jasper Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of Common Stock for Continued Listing on the Nasdaq Capital Market

Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

Less than half of directors are independent

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics Receives Written Notice from Nasdaq Regarding Minimum $1.00 Per Share Requirement

Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes

Price target increased by 9.8% to US$6.88

New major risk - Revenue and earnings growth

Jasper Therapeutics Strengthens Management Team with Key Appointments

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jasper Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

Jasper Therapeutics, Inc. Appoints Scott Brun to Its Board of Directors

CFO, COO & Corporate Secretary notifies of intention to sell stock

Jasper Therapeutics, Inc. Announces Appointment of Edwin J. Tucker as Chief Medical Officer

Jasper Therapeutics, Inc. Announces Appointment of Stephen J. Galli to Scientific Advisory Board

Jasper Therapeutics, Inc. Appoints Vishal Kapoor as Class I Director

Price target increased by 11% to US$5.97

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target decreased by 9.0% to US$7.10

Jasper Therapeutics, Inc. Announces New Positive Briquilimab Data to Be Presented at the 2023 Tandem Meetings

Jasper Therapeutics, Inc. Announces Development Prioritization of Briquilimab in Chronic Diseases

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as A Conditioning Treatment for Patients Prior to Receiving A Stem Cell Transplant

Jasper Therapeutics, Inc. Announces Positive Clinical Data from A Phase I/Ii Trial of Briquilimab as A Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

Price target decreased to US$7.80

High number of new directors

Price target decreased to US$12.00

Jasper Therapeutics Receives Written Notice from Nasdaq

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, A Novel Monoclonal Antibody Targeting CD117, in the Treatment of Patients with Severe Combined Immunodeficiency (SCID) Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Price target decreased to US$12.25

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Non-Executive Chairperson of the Board notifies of intention to sell stock

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

Jasper Therapeutics, Inc. Announces Development of Novel Curative Therapies Based on the Biology of the Hematopoietic Stem Cell

Jasper Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

Jasper Therapeutics, Inc. Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

High number of new directors

Jasper Therapeutics, Inc. Announces Executive Changes

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

No independent directors

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera